Enoxaparin
Authors:
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 62 (9) , 1407-1430
Abstract
Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) indicated for use in the treatment of ischaemic complications of unstable angina and non-Q wave myocardial infarction (MI). Unfractionated heparin (UFH) has for many years represented the standard in anticoagulant therapy for patients with acute coronary syndromes; however, recent studies suggest that enoxaparin is also a viable option for anticoagulant therapy in these patients. The ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events) and the TIMI 11B (Thrombolysis in Myocardial Infarction) studies reported that twice daily enoxaparin was significantly more effective than a continuous infusion of UFH in reducing the composite triple endpoint of death, MI, or recurrent angina or urgent revascularisation. Follow-up of both patient populations showed continued benefit associated with enoxaparin. Enoxaparin has been compared with tinzaparin in the treatment of unstable coronary artery disease using a nonblind study design. There was no difference between treatment groups in the therapeutic endpoints. Three nonblind studies have also compared the effects of enoxaparin and UFH in patients receiving thrombolytic therapy following acute MI. The HART II (Heparin and Aspirin Reperfusion Therapy), the ASSENT 3 (Assessment of the Safety and Efficacy of a New Thrombolytic Regimen) and the ENTIRE-TIMI23 (Enoxaparin and Tenecteplase with or without glycoprotein IIb/IIIa Inhibitor as Reperfusion strategy in ST Elevation MI — Thrombolysis in Myocardial Infarction) studies have revealed that enoxaparin in combination with alteplase or tenecteplase is at least equivalent (HART II and ENTIRE-TIMI 23), and possibly superior (ASSENT 3) to UFH. Enoxaparin is administered as a twice-daily subcutaneous injection. In contrast, UFH is administered as an intravenous infusion which requires routine monitoring of the activated partial thromboplastin time to ensure adequate levels of anticoagulation are maintained. During the acute phase of the the ESSENCE and TIMI 11B studies, the incidence of major bleeding was similar in patients receiving enoxaparin to that in patients receiving UFH. In contrast, the rates of minor bleeding were higher in patients receiving enoxaparin than in those receiving UFH throughout these studies. Conclusions: Data from the ESSENCE, TIMI 11B and ASSENT 3 studies have prompted calls for those LMWHs which have been shown to be superior to UFH, to be considered as first choice treatment for anticoagulation in unstable coronary syndromes. To date, these suggestions are not reflected in current guidelines which consider UFH and LMWHs equally. Irrespective, the clinical data reported in this review support the use of enoxaparin in the treatment of acute coronary syndromes. These data suggest that enoxaparin shows certain clinical and practical advantages over standard treatment with UFH and represents an important development in the treatment of acute coronary syndromes. Enoxaparin (enoxaparin sodium) is produced through depolymerisation of unfractionated heparin (UFH) and consists of polysaccharide chains with an average molecular weight of about 4 to 5kD. The primary anticoagulant effect of enoxaparin is mediated via a conformational interaction with antithrombin III which, in turn, inactivates procoagulatory serine proteases. Thus, the indirect consequence of enoxaparin is inhibition of the conversion of prothrombin to thrombin, thus reducing the thrombin-mediated conversion of fibrinogen to fibrin and preventing the formation of clots. In pharmacodynamic studies, enoxaparin inhibited thrombus formation but had only minor effects on platelet activation. Enoxaparin had little effect on platelets in vivo [in patients with unstable angina (UA)] and ex vivo (from volunteers), whereas UFH activated platelets in vivo and enhanced platelet aggregability ex vivo. However, other clinical evidence suggests that UFH is a more potent inhibitor of platelet aggregation than enoxaparin. Enoxaparin also inhibits platelet prothrombinase activity and tissue factor-mediated prothrombinase assembly in blood samples taken from patients receiving enoxaparin for the treatment of UA/non-ST-segment elevation myocardial infarction (MI). Plasma samples taken from these patients 1 and 30 hours after initiation of enoxaparin treatment indicated that the drug inhibited tissue factor-mediated prothrombinase assembly by 31.2 and 11.3%, respectively, and platelet prothrombinase activity by 27.5 and 21.9%, respectively. The pharmacokinetics of enoxaparin are based on measurement of antifactor Xa activity. Following subcutaneous administration, the bioavailability of enoxaparin is 92% and time to reach peak plasma antifactor Xa activity is 3 to 5 hours. There is a linear dose relationship for antifactor Xa activity and the area under the antifactor Xa activity-time curve over the dose range 20 to 80mg. Elimination half-life (t½) of enoxaparin is 4.5 hours, and elimination is via the kidneys and independent of dosage. In patients with end-stage renal disease t½ is prolonged to 8.2 hours and apparent total body clearance is 0.0114 L/h/kg. In obese but otherwise healthy volunteers, the maximum amount of the drug in the body was 15% higher and t½was 9% longer than that in healthy volunteers. These differences were attributed to the weight-adjusted dosage used in this study. In Patients with Non- ST Segment Elevation Acute Coronary Syndromes The ESSENCE study (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events) was a double-blind, double-dummy, placebo-controlled study performed in patients who had experienced angina at rest or with non-Q wave MI. 3171 patients were randomised to receive subcutaneous enoxaparin (n = 1607; 1 mg/kg every 12 hours) or UFH (n = 1564) as an intravenous bolus (usually 5000IU) followed by a continuous infusion at a...Keywords
This publication has 35 references indexed in Scilit:
- ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarctionJACC, 2000
- Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52.JACC, 2000
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisThe Lancet, 2000
- Heparin-Induced ThrombocytopeniaDrugs & Aging, 2000
- Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)European Heart Journal, 1999
- EnoxaparinDrugs, 1998
- Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarctionThe American Journal of Cardiology, 1996
- New Data on the Pharmacology of Heparin and Low Molecular Weight HeparinsDrugs, 1996
- EnoxaparinDrugs, 1995
- EnoxaparinDrugs, 1992